📰 Simcere Pharmaceutical News
Page 2 - Simcere Pharmaceutical News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Simcere Pharmaceutical. Real-time updates on events, politics, business and more.
September 5, 2022
/PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) announced its financial results for the first half of 2022. As of June 30, Simcere recorded...
July 13, 2022
Ascletis Pharma (ASCLF) is ready to put its new Covid drug into clinical trials, but the firm is lagging in the race to bring similar medicines to market. Read more.
May 27, 2022
Worldwide Healthcare Trust Plc - Audited Results for the year ended 31 March 2022 PR Newswire London, May 27 LONDON STOCK EXCHANGE ANNOUNCEMENT Worldwide Healthcare
April 19, 2022
/PRNewswire/ -- On April 15, 2022, Simcere Pharmaceutical (2096.HK), an innovation and R&D driven pharmaceutical company in China held its first R&D day for...
August 27, 2021
Kazia says its future success will be measured by commercialisation milestones after the company recorded its maiden revenue in the 2021 financial year.
April 30, 2021
Kazia Therapeutics lands trifecta of licensing deals in March quarter, leaving it "a vastly stronger and more substantial business" During the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million end-March. These transactions leave Kazia a vastly stronger and more substantial business, with a diversified pipeline of world-class oncology assets. Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FR...
April 19, 2021
Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 DGAP-News: Evotec SE / Key word(s): Miscellaneous 19.04.2021 / 08:31 The issuer is solely responsible for the content of this announcement. EVOTEC GRANTS KAZIA THERAPEUTICS AN EXCLUSIVE WORLDWIDE LICENSE FOR DEVELOPMENT AND COMMERCIALISATION OF ONCOLOGY ASSET EVT801 KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURI...
April 19, 2021
Evotec AG: Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURING AND CONTROLS ("CMC") EVOTEC RECEIVES A SMALL UPFRONT PAYMENT AS WELL AS RESEARCH FUNDING TO DEVELOP A BIOMARKER, AND IS ELIGIBLE TO RECEIVE CLINICAL AND COMMERCIAL MILESTONES AS WELL AS TIERED ROYALTIES ON THE NET SALES HAMBURG, GERMANY / ACCESSWIRE / April 19, 2021 / Evotec SE ...
April 19, 2021
Message : Required fields DGAP-News: Evotec SE / Key word(s): Miscellaneous Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 2021-04-19 / 08:31 The issuer is solely responsible for the content of this announcement. =---------------------------------------------------------------------------------------------------------------------- . EVOTEC GRANTS KAZIA THERAPEUTICS AN EXCLUSIVE WORLDWIDE LICENSE FOR DEVELOPMENT AND COMMERCIALISATION OF ONCOLOGY ...
April 9, 2021
Kazia Therapeutics Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused drug development company, is pleased to share new data from its ongoing phase II study of paxalisib in glioblastoma, the most common and most aggressive form of primary brain cancer. The data is the subject of a poster presentation at the American Association of Cancer Research (AACR) Annual Meeting, which is being held virtually from 10-15 April 2021, and from 17-21 May 2021. Key...